AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$NTRA

Rabinowitz Matthew sold $700K of NTRA (indirect holdings)

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 2,000 indirectly-held shares of Natera, Inc. (NTRA) at $350.01 ($0.70M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Sep 17, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, which can be factored into short‑term trading decisions.

02

Market read

Insider sale of $700K may influence NTRA's stock price in the near term.

03

What to watch

Potential upcoming financing needs or personal tax planning may have driven the sale.

Relevance 4/10Novelty 7/10Timing: post‑filing 2026‑09‑16

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Executive Chairman Matthew Rabinowitz sold 2,000 shares for $700K via a 10b5‑1 plan, reducing his stake to zero.

Expected impact

Potential modest downside pressure in the short term.

Evidence & confidence

A $700K sale by the executive chairman is material but not unusually large; market may view it as a negative signal.

Market effects

Sector

Minimal impact on the broader biotech sector; only reflects company‑specific insider activity.

Regional

No regional effect beyond Natera's share price.

Global

Limited global relevance; primarily of interest to NTRA investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Executive Chairman
    Matthew Rabinowitz

    Executive Chairman of Natera who executed the sale.

  • Company
    Natera, Inc.

    US‑listed biotech company (ticker NTRA).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

SEP 9
$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

yahoo.com2 min
SEP 2
$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

etfdb.com3 min
AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min